secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioRestorative Therapies, Inc. (BRTX)
CIK:        0001505497
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001021771-24-000140
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

BioRestorative Therapies restates financials due to warrant classification error; no cash impact
--------------------------------------------------------------------------------

- Previously issued annual (FY2023) and quarterly (Q1'22–Q3'23) financial statements should no longer be relied upon.
- Restatement reclassifies 2,645,000 public warrants ($10 exercise), 1,856,938 private warrants ($10), and 235,970 underwriter warrants ($12.50) from equity to liabilities.
- Non-cash adjustments affect balance sheet and fair value changes in operations; no impact on cash, revenue, operating expenses, or loss from operations.
- Company plans to file amended 10-K by June 28, 2024, and concurrently file Q1 2024 10-Q.
- Audit committee discussed matter with independent auditor Marcum LLP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1505497/000102177124000140/0001021771-24-000140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1505497/000102177124000140/brt8k523.htm
  HTML page:      https://secwatch.observer/filing/0001021771-24-000140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer